Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutationsHanako Hasegawa, Kenzo Soejima, Hiroyuki Yasuda et al.|Lung Cancer|2018Cited by 50
Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancerKeiko Ohgino, Tomoko Betsuyaku, Kenzo Soejima et al.|Lung Cancer|2013Cited by 49
Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung CancerKota Ishioka, Koichi Fukunaga, Tetsuo Tani et al.|Cancer Research|2021Cited by 43
Intracellular levels of reactive oxygen species correlate with ABT‐263 sensitivity in non‐small‐cell lung cancer cellsKeiko Ohgino, Kenzo Soejima, Hideki Terai et al.|Cancer Science|2020Cited by 13
Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)Masayoshi Miyawaki, Kenzo Soejima, Katsuhiko Naoki et al.|Molecular and Clinical Oncology|2017Cited by 10